Cellectar Biosciences Inc (CLRB)
2.20
+0.04
(+1.85%)
USD |
NASDAQ |
Oct 04, 16:00
2.195
0.00 (0.00%)
After-Hours: 20:00
Cellectar Biosciences SG&A Expense (Annual): 10.75M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.75M |
| December 31, 2022 | 9.594M |
| December 31, 2021 | 6.545M |
| December 31, 2020 | 5.150M |
| December 31, 2019 | 5.183M |
| December 31, 2018 | 4.820M |
| December 31, 2017 | 4.135M |
| December 31, 2016 | 4.699M |
| December 31, 2015 | 3.395M |
| December 31, 2014 | 3.705M |
| Date | Value |
|---|---|
| December 31, 2013 | 4.445M |
| December 31, 2012 | 3.632M |
| December 31, 2011 | 2.692M |
| December 31, 2010 | 1.156M |
| December 31, 2009 | 2.182M |
| December 31, 2008 | 2.190M |
| December 31, 2007 | 2.866M |
| December 31, 2006 | 2.488M |
| December 31, 2005 | 1.443M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
5.150M
Minimum
2020
10.75M
Maximum
2023
7.444M
Average
6.545M
Median
2021
SG&A Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.06M |
| Actinium Pharmaceuticals Inc | 13.33M |
| Chimerix Inc | 24.60M |
| Marinus Pharmaceuticals Inc | 61.15M |
| Jaguar Health Inc | 23.05M |